AIR Option 2: Research Alliance - Ecosystem for Biophotonic Innovation (EBI) Building Sustainability

AIR 选项 2：研究联盟 - 生物光子创新生态系统 (EBI) 建设可持续发展

• 批准号: 1343479
• 负责人: Dennis Matthews
• 金额: $ 80万
• 依托单位: University of California-Davis
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-10-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1343479&HistoricalAwards=false
• 关键词: AIR; Option; Research; Alliance; Ecosystem

This PFI: AIR Research Alliance project focuses on building a sustainable innovation ecosystem in biophotonics, on educating the next generation of entrepreneurs and on accelerating the translation and transfer of key biomedical technologies developed by an NSF Science and Technology Center (STC), the Center for Biophotonics Science and Technology (CBST). The technologies proposed for commercialization in collaboration with our partners will fill technology gaps in the following areas: 1) super-resolution cellular imaging for biology and medicine, 2) novel non-photobleaching labels for imaging of cell dynamics, 3) monitoring cellular response to cancer drugs, and 4) automated blood pathology for disease detection and monitoring. These technologies have the following market-valued features: 1) outstanding image quality at resolutions that are at least 8 times higher (volume-wise) than the diffraction limit, that provide exemplary performance at lower, and thus more forgiving, illumination intensities when compared to leading optical microscopy technologies; 2) provide the ability to use non-photobleaching SERS (surface enhanced Raman scattering) labels for cellular imaging of cell dynamics, for monitoring unique biomarkers that cannot yet be monitored with other techniques; 3) capability to monitor cellular responses to cancer drugs in almost real-time by using Raman cytometry and in a more efficient manner compared with other experimental strategies; and 4) automated, real-time, point-of-care blood testing systems that provide enormous cost savings when compared to impedance-based, large, skilled labor-intensive and expensive commercially-available blood pathology systems. The Ecosystem for Biophotonics Innovation accomplishes this transfer to the market either by working in collaboration with research partners and transferring technologies to them, or via spinoffs, resulting in creation of new jobs (Entrepreneurial Fellows in academia, scientists collaborators in industry, and scientists in startup companies), commercial products for biology and medicine, with the potential to advance research and help patients while also training entrepreneurial scientists and generating licensing and royalty revenues. The partnerships engaged to transfer the technologies to the market domain include: 1) Applied Precision Inc, a GE Healthcare Company - will commercialize software algorithms for next generation super-resolution microscopes; 2) BD Biosciences - will commercialize novel SERS labels for studying cell dynamics; 3) Keaton Raphael Memorial foundation - will invest financial resources to advance technologies for diagnosis and treatment of pediatric cancers and to launch a startup company to commercialize the most promising technologies; 4) SARTA - will provide links to entrepreneurs in the region and educational opportunities; and 5) Tahoe Institute for Rural Health Research - will commercialize the automatic blood pathology system. The potential economic impact is expected to be realized through: 1) employing highly skilled and productive entrepreneurial fellows, faculty, as well as the scientists at our partnering organizations; 2) employing highly skilled scientists in spinoff companies; 3) licensing of technologies; and 4) through product sales (e.g., next generation super-resolution optical microscopes, labels and assays for cellular imaging, assays for monitoring cellular response to cancer drugs, and automated pathology systems), in the next one-to-five years. All these activities will ultimately contribute to the U.S. competitiveness in the biomedical technology market space through ensuring that cutting-edge technologies are commercialized in the U.S. instead of by scientists and companies from other countries and through providing excellent professional development opportunities to talented entrepreneurial fellows who we expect will have innovative and resourceful careers beyond their tenure with EBI. In the short term, the societal impact includes the movement of advanced technologies closer to commercialization, as well as hands-on training and learning for the next generation of scientists and entrepreneurs regardless of whether entrepreneurial fellows pursue careers in academia or in the private sector. In the long term, the societal impact includes enhancement of scientific discovery enabled by cutting-edge instruments, medical devices, techniques and assays, better understanding of biophysical phenomena, and ultimately improved patient care. EBI will also benefit society by strengthening an infrastructure to promote innovation and to educate would-be entrepreneurs, while also enabling universities to more productively partner with private industry.

该PFI：空气研究联盟项目着重于在生物植物学中建立可持续的创新生态系统，教育下一代企业家，并加快由NSF科学技术中心（STC）开发的关键生物医学技术的翻译和转移，该中心是生物涉及科学和技术中心（CBST）。与我们的合作伙伴合作进行商业化的技术将填补以下领域的技术空白：1）生物学和医学的超分辨率蜂窝成像，2）用于细胞动力学成像的新型非透明标签，3）监测细胞对癌症药物的反应，4）4）疾病检测和监测自动血液病理学。这些技术具有以下市场价值的特征：1）与领先的光学显微镜技术相比，在较低的衍射限制的分辨率（至少比衍射限制）高8倍（音量）的杰出图像质量； 2）提供了使用非透射SERS（表面增强的拉曼散射）标签进行细胞动力学成像的能力，以监视无法使用其他技术监测的独特生物标志物； 3）与其他实验策略相比，通过使用拉曼细胞仪和更有效的方式，几乎实时监测细胞对癌症药物的反应的能力； 4）与基于阻抗，大型，熟练的劳动力密集型且昂贵的商业性血液病理系统相比，自动化，实时的，护理点的血液测试系统可节省大量成本。 生物素养创新的生态系统通过与研究伙伴合作并将技术转移给他们，或者通过衍生产品来实现这一转移到市场，从而创造了新工作，从而创造了新工作（企业家研究员（企业家研究员）（企业家，科学家的行业中的科学家合作者，以及与初创企业中的科学家和医学生物的培训），同时培训生物学和医学生物学，以帮助生物学和医学生物学，，，商业化的生物学，医学生物学），，商业化的生物学，医学生物学），，培养业人士，商业化的生物学和医学，，，企业家的培训者），，培养业。许可和特许权使用费收入。将技术转移到市场领域的合作伙伴关系包括：1）GE Healthcare Company Applied Precision Inc-将使下一代超分辨率显微镜的软件算法商业化； 2）BD Biosciences-将商业化新型SERS标签用于研究细胞动力学； 3）Keaton Raphael Memorial Foundation-将投资财政资源来推进诊断和治疗儿科癌症的技术，并成立一家初创公司，以商业化最有希望的技术； 4）Sarta-将提供与该地区企业家和教育机会的联系； 5）塔霍农村健康研究所 - 将使自动血液病理系统商业化。预计将通过以下方式实现潜在的经济影响：1）采用高技能和高产的企业家研究员，教师以及我们合作组织的科学家； 2）在分拆公司中雇用高技能的科学家； 3）技术许可； 4）通过产品销售（例如，下一代超分辨率光学显微镜，用于细胞成像的标签和测定，监测对癌症药物的细胞反应的测定以及自动化病理系统），在接下来的一到五年中。所有这些活动最终将通过确保在美国而不是由其他国家的科学家和公司进行商业化，并通过为我们期望的有才华的企业家研究员提供出色的专业发展机会，从而有助于美国在生物医学技术市场领域的竞争力，我们希望他们能在EBI中拥有创新和机智的职业。在短期内，社会影响包括更接近商业化的先进技术，以及下一代科学家和企业家的动手培训和学习，无论企业家研究员是从事学术界还是私营部门的职业。从长远来看，社会影响包括通过最先进的仪器，医疗设备，技术和测定，对生物物理现象的更好理解，并最终改善患者护理来增强科学发现。 EBI还将通过加强基础设施来促进创新和教育潜在的企业家，同时还可以使大学能够与私营企业更有效地合作，从而使社会受益。